Search Results for: RB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CRYBA4 crystallin beta A4
  • Anophthalmia and microphthalmia (A/M)
Novel CDADC1 cytidine and dCMP deaminase domain containing 1
Novel CNTN3 contactin 3
  • Post-translational modification: synthesis of GPI-anchored proteins
Novel COX17 cytochrome c oxidase copper chaperone COX17
  • Mitochondrial protein import
Novel CSK C-terminal Src kinase
  • GAB1 signalosome
  • Phosphorylation of CD3 and TCR zeta chains
  • Integrin signaling
  • PD-1 signaling
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Negative regulation of FLT3
  • Dasatinib
  • Staurosporine
  • TG-100801
  • Fostamatinib
Novel ESD esterase D
  • Glutathione conjugation
  • Glutathione
Novel LRCH1 leucine rich repeats and calponin homology domain containing 1
Novel MTRF1 mitochondrial translation release factor 1
Novel PCDHB5 protocadherin beta 5
TP53 tumor protein p53
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Factors involved in megakaryocyte development and platelet production
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Osteosarcoma
  • Adrenal carcinoma
  • Thyroid cancer
  • Breast cancer
  • Basal cell carcinoma
  • Malignant melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Small cell lung cancer
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Glioma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Cancer of the anal canal
  • Hepatocellular carcinoma
  • Choriocarcinoma
  • Vulvar cancer
  • Choroid plexus papilloma
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Hairy-cell leukemia
  • Bladder cancer
  • Chronic lymphocytic leukemia (CLL)
  • Penile cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Colorectal cancer
  • Laryngeal cancer
  • Chronic myeloid leukemia (CML)
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
LMNA lamin A/C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CCND1 cyclin D1
  • SCF(Skp2)-mediated degradation of p27/p21
  • Pre-NOTCH Transcription and Translation
  • RMTs methylate histone arginines
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional Regulation by VENTX
  • Transcriptional regulation by RUNX2
  • Regulation of RUNX1 Expression and Activity
  • RUNX3 regulates WNT signaling
  • RUNX3 regulates p14-ARF
  • Estrogen-dependent gene expression
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Acetylsalicylic acid
  • Arsenic trioxide
  • Encorafenib
  • Bryostatin 1
  • Hairy-cell leukemia
  • von Hippel-Lindau syndrome
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Laryngeal cancer
  • Breast cancer
MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
  • Penile cancer
  • Alveolar rhabdomyosarcoma
AR androgen receptor
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • RUNX2 regulates osteoblast differentiation
  • RUNX2 regulates osteoblast differentiation
  • Diethylstilbestrol
  • Levonorgestrel
  • Progesterone
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Fluphenazine
  • Testosterone
  • Mitotane
  • Estrone
  • Nilutamide
  • Tamoxifen
  • Norethisterone
  • Drostanolone
  • Norgestimate
  • Nandrolone phenpropionate
  • Ketoconazole
  • Acetophenazine
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone propionate
  • Oxybenzone
  • 1-Testosterone
  • Boldenone
  • Calusterone
  • Periciazine
  • Prasterone
  • Flufenamic acid
  • Stanolone
  • (R)-Bicalutamide
  • Metribolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone acetate
  • LGD2941
  • Dimethylcurcumin
  • Oxymetholone
  • Methyltestosterone
  • Norelgestromin
  • Stanozolol
  • Tetrahydrogestrinone
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • BMS-564929
  • S-23
  • phenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • Andarine
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • LGD-2226
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Triclosan
  • Nandrolone decanoate
  • Ulipristal
  • Enzalutamide
  • Eugenol
  • Dienogest
  • Norethynodrel
  • Norgestrel
  • Homosalate
  • Enzacamene
  • Mibolerone
  • Phenothiazine
  • Gestrinone
  • Apalutamide
  • Clascoterone
  • Darolutamide
  • Esculin
  • Ligandrol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Segesterone acetate
  • Boldenone undecylenate
  • Echinacoside
  • Ketodarolutamide
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
  • 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
  • Prostate cancer
  • Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
INS insulin
  • Regulation of gene expression in beta cells
  • Insulin processing
  • Insulin processing
  • Synthesis, secretion, and deacylation of Ghrelin
  • Regulation of insulin secretion
  • COPI-mediated anterograde transport
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Amyloid fiber formation
  • Zinc
  • M-Cresol
  • Myristic acid
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Maturity onset diabetes of the young (MODY)
  • Type I diabetes mellitus
  • Permanent neonatal diabetes mellitus (PNDM)
PAX6 paired box 6
  • Regulation of gene expression in beta cells
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Aniridia
  • Polymicrogyria; Bilateral frontal polymicrogyria (BFP); Bilateral frontoparietal polymicrogyria (BFPP); Bilateral perisylvian polymicrogyria (BPP); Bilateral parasagittal parieto-occipital polymicrogyria (BPOP); Bilateral generalised polymicrogyria (BGP); Unilateral Polymicrogyria (ULP)
  • Ocular coloboma, including: Coloboma of iris choroid and retina (COI); Coloboma of optic nerve (COLON)
PPARG peroxisome proliferator activated receptor gamma
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • MECP2 regulates transcription factors
  • alpha-Linolenic acid
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Valproic acid
  • Indomethacin
  • Rosiglitazone
  • Fenoprofen
  • Nateglinide
  • Sulfasalazine
  • Clofazimine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Amiodarone
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • Flufenamic acid
  • Resveratrol
  • Phthalic Acid
  • Capric acid
  • Doconexent
  • Oleic Acid
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • Reglitazar
  • Elafibranor
  • AMG-131
  • CLX-0921
  • Muraglitazar
  • Ertiprotafib
  • Ragaglitazar
  • Tesaglitazar
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • 9(S)-HODE
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • Indeglitazar
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • Triclosan
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • Aleglitazar
  • Clinofibrate
  • Cannabidiol
  • Lobeglitazone
  • Ciglitazone
  • Dexibuprofen
  • Omega-3 fatty acids
  • Curcumin
  • Arhalofenate
  • Isoflavone
  • Naveglitazar
  • Fenofibric acid
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Darglitazone
  • Curcumin sulfate
  • Type II diabetes mellitus
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Thyroid cancer
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)

Page 1 out of 10 pages